166 related articles for article (PubMed ID: 36151848)
1. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Thirasastr P; Lin H; Amini B; Wang WL; Cloutier JM; Nassif EF; Keung EZ; Roland CL; Feig B; Araujo D; Benjamin RS; Conley AP; Livingston JA; Ludwig J; Patel S; Ratan R; Ravi V; Zarzour MA; Zhou X; Somaiah N
Cancer Med; 2023 Feb; 12(4):4282-4293. PubMed ID: 36151848
[TBL] [Abstract][Full Text] [Related]
2. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
Matsuda S; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
[TBL] [Abstract][Full Text] [Related]
3. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center.
Nassif EF; Cope B; Traweek R; Witt RG; Erstad DJ; Scally CP; Thirasastr P; Zarzour MA; Ludwig J; Benjamin R; Bishop AJ; Guadagnolo BA; Ingram D; Wani K; Wang WL; Lazar AJ; Torres KE; Hunt KK; Feig BW; Roland CL; Somaiah N; Keung EZ
Int J Cancer; 2022 Jun; 150(12):2012-2024. PubMed ID: 35128664
[TBL] [Abstract][Full Text] [Related]
4. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
5. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin.
Fabbroni C; Fucà G; Ligorio F; Fumagalli E; Barisella M; Collini P; Morosi C; Gronchi A; Dei Tos AP; Casali PG; Sanfilippo R
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810165
[TBL] [Abstract][Full Text] [Related]
6. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
7. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
[TBL] [Abstract][Full Text] [Related]
8. Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Higuchi T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(4):351-358. PubMed ID: 32576580
[TBL] [Abstract][Full Text] [Related]
9. Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.
Zhou MY; Bui NQ; Charville GW; Ganjoo KN; Pan M
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298520
[TBL] [Abstract][Full Text] [Related]
10. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
12. Does "Low-Grade" Dedifferentiated Liposarcoma Exist? The Role of Mitotic Index in Separating Dedifferentiated Liposarcoma From Cellular Well-differentiated Liposarcoma.
Graham DS; Qorbani A; Eckardt MA; Klingbeil KD; Chen LY; Chopra S; Eilber FC; Dry SM
Am J Surg Pathol; 2023 Jun; 47(6):649-660. PubMed ID: 37057834
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma].
Guo X; Zhuang RY; Zhou YH; You CL; Zhang Y; Feng F; Shen ZM; Wang WS; Liu Y; Zhang HX; Tong WQ; Lu RK; Luo R
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2428-2434. PubMed ID: 36000371
[No Abstract] [Full Text] [Related]
14. Detection of
Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
[TBL] [Abstract][Full Text] [Related]
15. What Are the Results of Resection of Localized Dedifferentiated Liposarcomas in the Extremities?
Nakata E; Kunisada T; Hasei J; Nakahara R; Yanai H; Toji T; Inoue Ct H; Ozaki T
Clin Orthop Relat Res; 2020 Nov; 478(11):2550-2561. PubMed ID: 33112583
[TBL] [Abstract][Full Text] [Related]
16. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.
Italiano A; Toulmonde M; Cioffi A; Penel N; Isambert N; Bompas E; Duffaud F; Patrikidou A; Lortal B; Le Cesne A; Blay JY; Maki RG; Schwartz GK; Antonescu CR; Singer S; Coindre JM; Bui B
Ann Oncol; 2012 Jun; 23(6):1601-7. PubMed ID: 22039081
[TBL] [Abstract][Full Text] [Related]
17. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
[TBL] [Abstract][Full Text] [Related]
18. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
Lu J; Wood D; Ingley E; Koks S; Wong D
Mol Biol Rep; 2021 Apr; 48(4):3637-3647. PubMed ID: 33893924
[TBL] [Abstract][Full Text] [Related]
19. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
[TBL] [Abstract][Full Text] [Related]
20. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
